Latest Tardive dyskinesia Stories
SAN DIEGO, June 23, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2), NBI-98854.
Results of the first, long-term clinical trial show the investigational drug safinamide may reduce dyskinesia (involuntary movements) in mid-to-late stage Parkinsonâ€™s disease.
Results of the first randomized, placebo-controlled long-term clinical trial show the investigational drug safinamide may reduce dyskinesia or involuntary movements in mid-to-late stage Parkinson's disease.
TITUSVILLE, N.J., April 11, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) on April 6 approved INVEGAÂ® (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age.
SAN DIEGO, April 5, 2011 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2), NBI-98854.
COMMACK, N.Y., Dec. 1, 2010 /PRNewswire/ -- The law office of Rudolph F.X. Migliore, P.C.
SAN DIEGO, Oct. 18 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has successfully completed a second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854.
ATLANTA, July 19 /PRNewswire/ -- The law firm of Childers, Schlueter & Smith, LLC of Atlanta, Georgia has announced that a jury trial involving the drug Reglan/metoclopramide will be held during the week of July 26, 2010. The case is Susan Swicegood v. Pliva et. al.
- The act of sweetening by admixture of some saccharine substance.